Contributors

Allen & Hanburys

Publication/Creation

London : Allen & Hanburys, 1968.

Persistent URL

https://wellcomecollection.org/works/ntys6mc8

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection 183 Euston Road London NW1 2BE UK T +44 (0)20 7611 8722 E library@wellcomecollection.org https://wellcomecollection.org





Dequadin Lozenges

For rapid control of infections of the mouth and throat

Dequadin – dequalinium chloride BP – possesses pronounced antibacterial and antimycotic properties. It has an exceptionally wide spectrum of activity and, in low concentration, inhibits nearly all bacteria pathogenic to man, including penicillin-resistant organisms. The action of Dequadin is not diminished in the presence of serum. The drawbacks associated with the topical use of antibiotics are well known. Dequadin Lozenges may be prescribed with confidence for patients of all ages, since they contain no antibiotic and therefore carry no risk of sensitisation, development of resistant strains or of secondary bacterial or fungal infection. Dequadin Lozenges do not contain a local anaesthetic.

Each lozenge contains 0.25 mg dequalinium chloride BP in a pleasantly flavoured sucrose base.

PRESENTATION AND BASIC NHS COST

Dequadin Lozenges are supplied in tubes of 20 and strip packs of 40. Basic NHS cost: 1/8d and 3/- respectively.

Full information is available on request.

Dequadin is a Trade Mark of

ALLEN & HANBURYS LIMITED LONDON E2

68/751/HN

Printed in England